NY-HCL-TECHNOLOGIES
20.8.2020 14:02:13 CEST | Business Wire | Press release
HCL Technologies , (HCL), a leading global technology company, today announced a multi-phase hackathon, “Better Health Hackathon: #CodeforCOVID19 ,” to crowdsource technology innovation to find solutions for the immediate and long-term societal impact of the COVID-19 pandemic, including pandemic containment and prevention; diagnosis, treatment and therapeutic management; recovery and return to normal; and systemic solutions for future crises.
As part of the program, HCL has partnered with Microsoft and International SOS , the world's largest medical and travel security services firm, who are providing business and technical oversight to the contest and feedback to team entries. In addition, the Better Health Hackathon is bringing together a wide-ranging and prestigious group of executives and companies, across multiple industries, to serve as judges and advisory panel members. This includes scholars from Johns Hopkins University, University of Cambridge, Tuck School of Business, The University of Queensland, Indian Institute of Technology, Kanpur, and subject matter experts from HCL.
The competition is open to technology innovators, entrepreneurs and problem solvers from the global developer community. To date the Better Health Hackathon has received more than 7500 registrations from 600+ unique organizations and academic institutions spanning 350 locations across 52 countries. To engage top talent in the coding community, the Hackathon is partnering with BeMyApp to leverage their expansive network of coders and tech enthusiasts. The Hackathon is open to eligible participants who are at least 18 years of age.
“The unique capabilities and strength of HCL’s global ecosystem of partners, coupled with the immense talent and best minds from the tech, developer and entrepreneur communities, enables us to make a significant contribution during the COVID-19 pandemic,” said Arthur Filip, Executive Vice President, Sales Transformation & Marketing, HCL Technologies. “Technology has a big role to play in alleviating the challenges brought on by the pandemic, addressing solutions for successful containment and the reorientation of business and society. We are honored to curate a very enthusiastic, committed and deeply talented global community to help us in this important work.”
Neeraj Balani, Managing Director, International SOS, India, said, “We are honored to be part of this initiative with our customer, HCL Technologies, and are confident that the outcomes will provide breakthroughs and benefits for employee health and wellness, which ultimately has a large impact on empowering business resilience, continuity and sustainability.”
Takuya Hirano, VP, Partner Services, Microsoft Corp., said, “This hackathon presents an opportunity for technology experts and innovative thinkers to showcase how advanced technology can help identify solutions to challenging problems facing societies. Technology can serve as a vehicle to drive new solutions that help improve the wellbeing of our communities and prepare us for future health challenges.”
Specifically, the HCL Better Health Hackathon: #CodeforCOVID19 will address the following areas:
-
Prevention and containment: #StayAtHome
- This track explores solutions that better safeguard the most vulnerable in our communities, better communicate credible information, and help people better cope with the challenges of self-isolation. This track will examine: How can technology aid efforts to #FlattenTheCurve by offering a better quality of life to encourage people to #StayAtHome.
-
Diagnosis, treatment & therapeutic management
- This track focuses on ways to help better protect and equip frontline healthcare workers and first responders, and to better serve those individuals and organizations seeking treatments and cures for COVID-19 with technology solutions.
-
Recovery and return to normal
- This track dives into the next phase of society after shutdown orders are removed. In the absence of a tested and available vaccine or therapeutic treatments against COVID-19, how can technology safeguard communities against a relapse of an outbreak, once social distancing and other restrictions are lifted throughout the world, allowing people to return to public spaces.
-
Systemic solutions for crises and pandemic management
- This track ideates innovative uses for next-gen technologies to plan for the long-term implications of COVID-19 and better prepare for future global pandemic-related challenges across healthcare and public services ecosystems.
About HCL Technologies
HCL Technologies (HCL) empowers global enterprises with technology for the next decade today. HCL’s Mode 1-2-3 strategy through its deep-domain industry expertise, customer-centricity and entrepreneurial culture of ideapreneurship™ enables businesses transform into next-gen enterprises.
HCL offers its services and products through three business units - IT and Business Services (ITBS), Engineering and R&D Services (ERS) and Products & Platforms (P&P). ITBS enables global enterprises to transform their businesses through offerings in areas of Applications, Infrastructure, Digital Process Operations and next generational digital transformation solutions. ERS offers engineering services and solutions in all aspects of product development and platform engineering while under P&P, HCL provides modernized software products to global clients for their technology and industry specific requirements. Through its cutting-edge co-innovation labs, global delivery capabilities and broad global network, HCL delivers holistic services in various industry verticals, categorized under Financial Services, Manufacturing, Technology & Services, Telecom & Media, Retail & CPG, Life Sciences & Healthcare and Public Services.
As a leading global technology company, HCL takes pride in its diversity, social responsibility, sustainability and education initiatives. As of 12 months ended June 30, 2020, HCL has a consolidated revenue of US $ 9.93 billion and its 150,287 ideapreneurs operate out of 49 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200820005438/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
